Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8 Debt-to-Equity is -0.74 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 815 Drug Manufacturers companies, BPH Global ranks worse than 122699.26% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BPH Global's Debt-to-Equity or its related term are showing as below:
ASX:BP8'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.74 Med: 0.06 Max: 0.46
Current: -0.74
During the past 13 years, the highest Debt-to-Equity Ratio of BPH Global was 0.46. The lowest was -0.74. And the median was 0.06.
ASX:BP8's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs ASX:BP8: -0.74
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BPH Global Debt-to-Equity Related Terms
BPH Global Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BPH Global's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BPH Global's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a Debt-to-Equity of -0.74 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BPH Global and its competitors. According to the industry distribution chart, BPH Global ranks #999999 out of 815 companies in the Drug Manufacturers industry.
Is BPH Global's Debt-to-Equity too high?
BPH Global's current Debt-to-Equity is -0.74. Based on the distribution chart, BPH Global ranks #999999 out of 815 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does BPH Global's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #999999 out of 815 companies for Debt-to-Equity. This places BPH Global in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Debt-to-Equity is -0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Debt-to-Equity of -0.74. The current Debt-to-Equity is -0.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Debt-to-Equity is -0.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
